• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Precision Medicine Startup 2bPrecise Brings Pharmacogenomics to the Point of Care

by HITC Staff 12/06/2017 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Mayo Clinic, 2bPrecise Partner to Develop Genomics-Based Clinical Decision Support Tools

2bPrecise., an EHR-agnostic, cloud-based precision medicine platform, recently announced its new pharmacogenomics (PGx) solution that takes pharmacogenetic information and makes it actionable for physicians. The solution pushes live, real-time PGx content directly into the clinical setting so clinicians can more precisely diagnose and treat their patients.

2bPrecise has partnered with Translational Software, Inc. (TSI), a leader in the intelligent use of genomic data for clinical decision support, to leverage its knowledge-base of PGx content.With adverse drug events causing over 770,000 injuries and deaths each year, physicians need actionable support tools in order to provide informed treatment decisions based on a patient’s unique genetic makeup.  

 2bPrecise’s PGx solution is part of its larger precision medicine platform, built to capture and store genomic data from a range of sources, enabling the harmonization clinical knowledge and genomic research to extract patient-specific insights. 2bPrecise’s unique approach to clinical workflow integration and dynamic content connectivity sets it apart from others in the pharmacogenomics space and helps future proof healthcare organization as genomic science advances. 

“What’s exciting about our partnership with 2bPrecise is that its technology pushes live, real-time PGx content beyond the lab, directly into the clinical setting,” said Don Rule, founder and CEO of Translational Software. “PGx data is no longer limited to a static interpretation at the time of result, allowing delivery of rich genomic insights to clinicians for more precisely diagnosing and treating their patients.”

 

2bPrecise chose to partner with TSI based on its robust knowledge-base of actively curated, evidence-based content. TSI’s proprietary knowledge platform provides genotyping prompts, genomic decision support and critical alerts regarding drug efficacy, toxicity and known interactions to guide clinical decision-making and enable physicians to prescribe the safest, most effective medications in real time. Content is maintained and curated so that changes are automatically reflected in TSI’s knowledge-base – vital given the rapid emergence of new PGx findings.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: pharmacogenomics

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |